Latest Boehringer Ingelheim Pharmaceuticals Inc. Stories

Boehringer Ingelheim also presents new data from a Phase 2 study demonstrating increased bronchodilation with 5 mcg tiotropium as an add-on therapy in symptomatic patients with moderate persistent asthma at the American Thoracic Society International Conference (ATS 2013) RIDGEFIELD, Conn., May 21, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of...

Data on investigational compounds and an approved product will be presented RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler®...

Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray will become the only available short-acting bronchodilator offering two different medicines in a single inhaler RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and patients that the transition to...

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds - afatinib* and nintedanib* - in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in...

For U.S. Media Only RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds - afatinib*, nintedanib* and volasertib*. Results - to be presented at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 - are from Boehringer Ingelheim's robust...

For U.S. Media Only RIDGEFIELD, Conn., May 7, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results of two surveys that explored how pulmonologists and pathologists are incorporating biomarker testing into the care of patients with lung cancer. The results point to an increased role of these physicians in biomarker testing as well as greater multidisciplinary collaboration. However, they also reveal that an opportunity exists to improve how...

Retrospective pooled analyses evaluated linagliptin treatment in American Hispanic/Latino people with type 2 diabetes, as well as in people living with type 2 diabetes for at least 10 years RIDGEFIELD, Conn. and INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented at the...

The SGLT disease education campaign provides resources for healthcare professionals about the role of sodium glucose co-transporters in maintaining blood sugar balance RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the launch of an educational campaign designed to provide healthcare professionals (HCPs) with a greater understanding of the role sodium glucose...

RIDGEFIELD, Conn., April 30, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced three important updates to the U.S. prescribing information for PRADAXA, an oral anticoagulant (OAC) indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The PRADAXA label now carries a Boxed Warning, similar to the Boxed Warnings in the labels of other new OACs, to advise patients that discontinuing treatment...

- STARTVerso(TM)1 data presented in treatment-naive patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin RIDGEFIELD, Conn., April 23, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the pivotal Phase 3 STARTVerso(TM)1 trial of faldaprevir (BI 201335) in combination with pegylated interferon and ribavirin (PegIFN/RBV). In previously untreated patients with genotype-1...